(Reuters) -India plans to cut personal income tax rates to boost middle-class spending power and seeks to increase private ...

Shardul Nautiyal, Mumbai Friday, January 31, 2025, 08:00 Hrs [IST] ...

Granules India's subsidiary, GPI, receives USFDA approval for Lisdexamfetamine Dimesylate Capsules, expanding ADHD treatment ...

Granules India receives FDA approval for generic ADHD drug, expanding portfolio and reinforcing presence in treatment space.

Lisdexamfetamine Dimesylate is indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in adults and ...

The Nifty Pharma index closed on a positive note on Thursday. Shares of Laurus Labs Ltd.(up 8.22 per cent), Granules India ...

Granules strengthens ADHD portfolio with US FDA approval for lisdexamfetamine dimesylate capsules: Our Bureau, Bengaluru Thursday, January 30, 2025, 16:15 Hrs [IST] Granules India ...

Granules India receives USFDA approval for its generic Lisdexamfetamine Dimesylate capsules, indicated for the treatment of ...

Gold futures on the Multi Commodity Exchange reached a record high of Rs 81,088 per 10 grams on Thursday, driven by strong ...

Hyderabad: Granules India Limited, a vertically integrated Indian pharmaceutical company, has announced that its wholly-owned ...

Pharmaceuticals firm, Granules India Ltd on Thursday said its arm has received a final nod from the US health regulator for its generic version of ...

IST, the barometer index, the S&P BSE Sensex, rallied 272.49 points or 0.35% to 76,808.15. The Nifty 50 index added 111.50 points or 0.48% to 23,274.60.